靶向药物发现。
Target class drug discovery.
机构信息
Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
Nat Chem Biol. 2017 Sep 19;13(10):1053-1056. doi: 10.1038/nchembio.2473.
Abstract
Selection of molecular targets based on disease understanding is a dominant paradigm in drug discovery. We argue that a focus on classes of targets with central roles in biology provides a complementary approach that has higher quality outcomes in early discovery efforts.
摘要
基于疾病认识选择分子靶标是药物发现的主导模式。我们认为，关注在生物学中具有核心作用的靶标类别提供了一种互补的方法，在早期发现工作中具有更高质量的结果。
相似文献
1
Target class drug discovery.
Nat Chem Biol. 2017 Sep 19;13(10):1053-1056. doi: 10.1038/nchembio.2473.
2
Drug discovery beyond the rule of 5 - Opportunities and challenges.
Expert Opin Drug Discov. 2017 Feb;12(2):115-119. doi: 10.1080/17460441.2017.1264385. Epub 2016 Dec 8.
3
Finding the rules for successful drug optimisation.
Drug Discov Today. 2014 May;19(5):680-7. doi: 10.1016/j.drudis.2014.01.005. Epub 2014 Jan 19.
4
Drug discovery, development and delivery in Alzheimer's disease.
Pharm Res. 2017 Dec 29;35(1):3. doi: 10.1007/s11095-017-2329-6.
5
The Drug Discovery Portal: a resource to enhance drug discovery from academia.
Drug Discov Today. 2010 Aug;15(15-16):679-83. doi: 10.1016/j.drudis.2010.06.003. Epub 2010 Jun 12.
6
Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery.
Drug Discov Today. 2017 Nov;22(11):1604-1619. doi: 10.1016/j.drudis.2017.07.007. Epub 2017 Jul 25.
7
Fragment-Based Drug Discovery--CHI's Fourth Annual Meeting. 6-7 April 2009, San Diego, CA, USA.
IDrugs. 2009 Jun;12(6):353-7.
8
Ion channels: applications in ion channel drug discovery.
Comb Chem High Throughput Screen. 2009 Jan;12(1):1. doi: 10.2174/138620709787048046.
9
Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery.
Arch Pharm Res. 2015 Sep;38(9):1627-41. doi: 10.1007/s12272-015-0618-3. Epub 2015 Jun 4.
引用本文的文献
1
Neuropilin-1-target self-assembled peptide nanoparticles contribute to tumor treatment by inducing pyroptosis.
BMC Cancer. 2025 Mar 6;25(1):413. doi: 10.1186/s12885-025-13784-y.
2
Protein Structure Inspired Discovery of a Novel Inducer of Anoikis in Human Melanoma.
Cancers (Basel). 2024 Sep 17;16(18):3177. doi: 10.3390/cancers16183177.
3
Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery.
iScience. 2024 Sep 3;27(10):110875. doi: 10.1016/j.isci.2024.110875. eCollection 2024 Oct 18.
4
The Art of Finding the Right Drug Target: Emerging Methods and Strategies.
Pharmacol Rev. 2024 Aug 15;76(5):896-914. doi: 10.1124/pharmrev.123.001028.
5
Protein Structure Inspired Drug Discovery.
bioRxiv. 2024 May 20:2024.05.17.594634. doi: 10.1101/2024.05.17.594634.
6
Trimethyllysine Reader Proteins Exhibit Widespread Charge-Agnostic Binding via Different Mechanisms to Cationic and Neutral Ligands.
J Am Chem Soc. 2024 Feb 7;146(5):3086-3093. doi: 10.1021/jacs.3c10031. Epub 2024 Jan 24.
7
Discovery of a 53BP1 Small Molecule Antagonist Using a Focused DNA-Encoded Library Screen.
J Med Chem. 2023 Oct 26;66(20):14133-14149. doi: 10.1021/acs.jmedchem.3c01192. Epub 2023 Oct 2.
8
Target Class Profiling of Small-Molecule Methyltransferases.
ACS Chem Biol. 2023 Apr 21;18(4):969-981. doi: 10.1021/acschembio.3c00124. Epub 2023 Mar 28.
9
Novel method to identify group-specific non-catalytic pockets of human kinome for drug design.
RSC Adv. 2020 Jan 10;10(4):2004-2015. doi: 10.1039/c9ra07471f. eCollection 2020 Jan 8.
10
Target 2035 - update on the quest for a probe for every protein.
RSC Med Chem. 2021 Dec 3;13(1):13-21. doi: 10.1039/d1md00228g. eCollection 2022 Jan 27.
本文引用的文献
1
Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing.
ACS Chem Biol. 2016 Sep 16;11(9):2475-83. doi: 10.1021/acschembio.6b00415. Epub 2016 Jul 14.
2
Chemical probes for methyl lysine reader domains.
Curr Opin Chem Biol. 2016 Aug;33:135-41. doi: 10.1016/j.cbpa.2016.06.004. Epub 2016 Jun 25.
3
Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca.
Drug Discov Today. 2016 Oct;21(10):1596-1608. doi: 10.1016/j.drudis.2016.06.007. Epub 2016 Jun 15.
4
The ins and outs of selective kinase inhibitor development.
Nat Chem Biol. 2015 Nov;11(11):818-21. doi: 10.1038/nchembio.1938.
5
Tackling reproducibility in academic preclinical drug discovery.
Nat Rev Drug Discov. 2015 Nov;14(11):733-4. doi: 10.1038/nrd4737. Epub 2015 Sep 21.
6
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Drug Discov Today. 2016 Jan;21(1):5-10. doi: 10.1016/j.drudis.2015.07.008. Epub 2015 Jul 23.
7
Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.
J Biol Chem. 2015 Aug 7;290(32):19471-7. doi: 10.1074/jbc.R115.654764. Epub 2015 Jun 22.
8
Targeting bromodomains: epigenetic readers of lysine acetylation.
Nat Rev Drug Discov. 2014 May;13(5):337-56. doi: 10.1038/nrd4286. Epub 2014 Apr 22.
9
Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.
Science. 2013 Jul 5;341(6141):84-7. doi: 10.1126/science.1233606.
10
Determining target engagement in living systems.
Nat Chem Biol. 2013 Apr;9(4):200-5. doi: 10.1038/nchembio.1211.
Zotero 插件